These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, ...

On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma” was accepted for ...

Please provide your email address to receive an email when new articles are posted on . KidneyIntelX is a prognostic test that incorporates machine learning and predictive biomarkers. Clinical ...

Telo Genomics Corp (TSE:TELO) has released an update. Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and ...

Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular ...

Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...

The use of Renalytix plc’s Kidneyintelx biomarker-based prognostic test led to increased and targeted use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients at risk of diabetic kidney ...